{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T05:49:27Z","timestamp":1745819367238,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Sanofi Korea"},{"DOI":"10.13039\/501100002551","name":"Seoul National University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002551","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s12325-024-02830-z","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T09:01:31Z","timestamp":1711011691000},"page":"1967-1982","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300\u00a0Units\/mL in Insulin-Na\u00efve Korean People with Type\u00a02 Diabetes: TOBE Study"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3390-5706","authenticated-orcid":false,"given":"Eun-Gyoung","family":"Hong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2266-9795","authenticated-orcid":false,"given":"Kyung-Wan","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4856-3462","authenticated-orcid":false,"given":"Jung Soo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4648-3605","authenticated-orcid":false,"given":"Kyu-Jeung","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3733-7486","authenticated-orcid":false,"given":"Chul Woo","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9179-1554","authenticated-orcid":false,"given":"Jae-Myung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6298-3506","authenticated-orcid":false,"given":"Hye Soon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6760-4963","authenticated-orcid":false,"given":"Hyun Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4067-8767","authenticated-orcid":false,"given":"Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4507-2038","authenticated-orcid":false,"given":"Dong Han","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4188-6536","authenticated-orcid":false,"given":"Hak Chul","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,21]]},"reference":[{"key":"2830_CR1","unstructured":"International Diabetes Federation (IDF). IDF diabetes atlas. 10th edition 2021. https:\/\/www.diabetesatlas.org\/en\/. Accessed Feb 13, 2024."},{"key":"2830_CR2","unstructured":"World Health Organization (WHO). Global report on diabetes. 2016. https:\/\/www.who.int\/diabetes\/global-report\/en\/. Accessed Feb 13, 2024."},{"key":"2830_CR3","unstructured":"World Health Organization (WHO). Diabetes fact sheet. 5 April 2023. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes. Accessed Feb 13, 2024."},{"issue":"402","key":"2830_CR4","first-page":"203","volume":"2023","author":"GBD 2021 Diabetes Collaborators","year":"2023","unstructured":"GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;2023(402):203\u201334.","journal-title":"Lancet"},{"key":"2830_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.4093\/dmj.2022.0106","volume":"46","author":"JH Bae","year":"2022","unstructured":"Bae JH, Han KD, Ko SH, et al. Diabetes fact sheet in Korea, 2021. Diabetes Metab J. 2022;46:417\u201326.","journal-title":"Diabetes Metab J"},{"key":"2830_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4093\/dmj.2018.42.2.93","volume":"42","author":"SH Ko","year":"2018","unstructured":"Ko SH, Han K, Lee YH, et al. Past and current status of adult type\u00a02 diabetes mellitus management in Korea: a national health insurance service database analysis. Diabetes Metab J. 2018;42:93\u2013100.","journal-title":"Diabetes Metab J"},{"key":"2830_CR7","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3803\/EnM.2016.31.3.349","volume":"31","author":"J Noh","year":"2016","unstructured":"Noh J. The diabetes epidemic in Korea. Endocrinol Metab (Seoul). 2016;31:349\u201353.","journal-title":"Endocrinol Metab (Seoul)"},{"key":"2830_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.4093\/dmj.2016.40.3.175","volume":"40","author":"BK Koo","year":"2016","unstructured":"Koo BK, Moon MK. Are we in the same risk of diabetes mellitus? Gender- and age-specific epidemiology of diabetes in 2001 to 2014 in the Korean population. Diabetes Metab J. 2016;40:175\u201381.","journal-title":"Diabetes Metab J"},{"key":"2830_CR9","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s12325-019-01199-8","volume":"37","author":"SN Ali","year":"2020","unstructured":"Ali SN, Dang-Tan T, Valentine WJ, Hansen BB. Evaluation of the clinical and economic burden of poor glycemic control associated with therapeutic inertia in patients with type\u00a02 diabetes in the United States. Adv Ther. 2020;37:869\u201382.","journal-title":"Adv Ther"},{"key":"2830_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1080\/13696998.2019.1645018","volume":"23","author":"SC Bain","year":"2020","unstructured":"Bain SC, Bekker Hansen B, Hunt B, Chubb B, Valentine WJ. Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type\u00a02 diabetes in the UK. J Med Econ. 2020;23:98\u2013105.","journal-title":"J Med Econ"},{"key":"2830_CR11","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.jdiacomp.2016.05.019","volume":"30","author":"SY Goh","year":"2016","unstructured":"Goh SY, Ang E, Bajpai S, et al. A patient-centric approach to optimise insulin therapy in Asia. J Diabetes Complications. 2016;30:973\u201380.","journal-title":"J Diabetes Complications"},{"key":"2830_CR12","doi-asserted-by":"publisher","first-page":"204201881984469","DOI":"10.1177\/2042018819844694","volume":"10","author":"S Khunti","year":"2019","unstructured":"Khunti S, Khunti K, Seidu S. Therapeutic inertia in type\u00a02 diabetes: prevalence, causes, consequences and methods to overcome inertia. Ther Adv Endocrinol Metab. 2019;10:2042018819844694.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2830_CR13","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/jdi.13352","volume":"12","author":"H Maegawa","year":"2021","unstructured":"Maegawa H, Ishigaki Y, Langer J, Saotome-Nakamura A, Andersen M, Japan Diabetes Clinical Data Management (JDDM) Study Group. Clinical inertia in patients with type\u00a02 diabetes treated with oral antidiabetic drugs: results from a Japanese cohort study (JDDM53). J Diabetes Investig. 2021;12:374\u201381.","journal-title":"J Diabetes Investig"},{"issue":"Suppl 1","key":"2830_CR14","first-page":"S1","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20142021. Diabetes Care. 2021;44(Suppl 1):S1\u20132.","journal-title":"Diabetes Care"},{"key":"2830_CR15","doi-asserted-by":"publisher","first-page":"398","DOI":"10.4093\/dmj.2019.0137","volume":"43","author":"MK Kim","year":"2019","unstructured":"Kim MK, Ko SH, Kim BY, et al. 2019 Clinical practice guidelines for type\u00a02 diabetes mellitus in Korea. Diabetes Metab J. 2019;43:398\u2013406.","journal-title":"Diabetes Metab J"},{"key":"2830_CR16","doi-asserted-by":"publisher","first-page":"367","DOI":"10.4093\/dmj.2017.41.5.367","volume":"41","author":"BW Lee","year":"2017","unstructured":"Lee BW, Kim JH, Ko SH, et al. Insulin therapy for adult patients with type\u00a02 diabetes mellitus: a position statement of the Korean Diabetes Association, 2017. Diabetes Metab J. 2017;41:367\u201373.","journal-title":"Diabetes Metab J"},{"key":"2830_CR17","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2337\/dc14-0006","volume":"38","author":"RH Becker","year":"2015","unstructured":"Becker RH, Dahmen R, Bergmann K, Lehmann A, Jax T, Heise T. New insulin glargine 300 Units\u00b7mL\u20131 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units\u00b7mL\u20131. Diabetes Care. 2015;38:637\u201343.","journal-title":"Diabetes Care"},{"key":"2830_CR18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.diabet.2017.04.007","volume":"43","author":"GB Bolli","year":"2017","unstructured":"Bolli GB, Riddle MC, Bergenstal RM, et al. Glycaemic control and hypoglycaemia with insulin glargine 300U\/mL versus insulin glargine 100U\/mL in insulin-na\u00efve people with type\u00a02 diabetes: 12-month results from the EDITION 3 trial. Diabetes Metab. 2017;43:351\u20138.","journal-title":"Diabetes Metab"},{"key":"2830_CR19","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/dom.13936","volume":"22","author":"L Ji","year":"2020","unstructured":"Ji L, Kang ES, Dong X, et al. Efficacy and safety of insulin glargine 300 U\/mL versus insulin glargine 100 U\/mL in Asia Pacific insulin-na\u00efve people with type\u00a02 diabetes: the EDITION AP randomized controlled trial. Diabetes Obes Metab. 2020;22:612\u201321.","journal-title":"Diabetes Obes Metab"},{"key":"2830_CR20","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/dom.13105","volume":"20","author":"R Ritzel","year":"2018","unstructured":"Ritzel R, Roussel R, Giaccari A, Vora J, Brulle-Wohlhueter C, Yki-J\u00e4rvinen H. Better glycaemic control and less hypoglycaemia with insulin glargine 300 U\/mL vs glargine 100 U\/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type\u00a02 diabetes. Diabetes Obes Metab. 2018;20:541\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"2830_CR21","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1111\/dom.12532","volume":"17","author":"H Yki-J\u00e4rvinen","year":"2015","unstructured":"Yki-J\u00e4rvinen H, Bergenstal RM, Bolli GB, et al. Glycaemic control and hypoglycaemia with new insulin glargine 300 U\/ml versus insulin glargine 100 U\/ml in people with type\u00a02 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension. Diabetes Obes Metab. 2015;17:1142\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"2830_CR22","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1111\/dom.13818","volume":"21","author":"TS Bailey","year":"2019","unstructured":"Bailey TS, Wu J, Zhou FL, et al. Switching to insulin glargine 300 units\/mL in real-world older patients with type\u00a02 diabetes (DELIVER 3). Diabetes Obes Metab. 2019;21:2384\u201393.","journal-title":"Diabetes Obes Metab"},{"key":"2830_CR23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2174\/1573399819666230109113205","volume":"19","author":"S Ghosh","year":"2023","unstructured":"Ghosh S, Kalra S, Bantwal G, et al. Use of second-generation basal insulin Gla-300 in special populations: a narrative mini-review. Curr Diabetes Rev. 2023;19:86\u201395.","journal-title":"Curr Diabetes Rev"},{"key":"2830_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108189","volume":"166","author":"M Hassanein","year":"2020","unstructured":"Hassanein M, Buyukbese MA, Malek R, et al. Real-world safety and effectiveness of insulin glargine 300 U\/mL in participants with type\u00a02 diabetes who fast during Ramadan: the observational ORION study. Diabetes Res Clin Pract. 2020;166:108189.","journal-title":"Diabetes Res Clin Pract"},{"key":"2830_CR25","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1111\/dom.13693","volume":"21","author":"TS Bailey","year":"2019","unstructured":"Bailey TS, Zhou FL, Gupta RA, et al. Glycaemic goal attainment and hypoglycaemia outcomes in type\u00a02 diabetes patients initiating insulin glargine 300 units\/mL or 100 units\/mL: real-world results from the DELIVER Na\u00efve cohort study. Diabetes Obes Metab. 2019;21:1596\u2013605.","journal-title":"Diabetes Obes Metab"},{"key":"2830_CR26","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s13300-022-01266-4","volume":"13","author":"GR Galstyan","year":"2022","unstructured":"Galstyan GR, Tirosh A, Vargas-Uricoechea H, et al. Real-world effectiveness and safety of insulin glargine 300 u\/ml in insulin-na\u00efve people with type\u00a02 diabetes: the ATOS study. Diabetes Ther. 2022;13:1187\u2013202.","journal-title":"Diabetes Ther"},{"key":"2830_CR27","doi-asserted-by":"publisher","first-page":"481","DOI":"10.4093\/dmj.2015.39.6.481","volume":"39","author":"SS Kim","year":"2015","unstructured":"Kim SS, Kim IJ, Kim YK, et al. Insulin initiation in insulin-na\u00efve Korean type\u00a02 diabetic patients inadequately controlled on oral antidiabetic drugs in real-world practice: the Modality of Insulin Treatment Evaluation Study. Diabetes Metab J. 2015;39:481\u20138.","journal-title":"Diabetes Metab J"},{"key":"2830_CR28","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/dom.13196","volume":"20","author":"S Chon","year":"2018","unstructured":"Chon S, Rhee SY, Ahn KJ, et al. Long-term effects on glycaemic control and \u03b2-cell preservation of early intensive treatment in patients with newly diagnosed type\u00a02 diabetes: a multicentre randomized trial. Diabetes Obes Metab. 2018;20:1121\u201330.","journal-title":"Diabetes Obes Metab"},{"key":"2830_CR29","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type\u00a02 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837\u201353.","journal-title":"Lancet"},{"key":"2830_CR30","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/dom.13607","volume":"21","author":"DR Owens","year":"2019","unstructured":"Owens DR, Landgraf W, Frier BM, et al. Commencing insulin glargine 100 U\/mL therapy in individuals with type\u00a02 diabetes: determinants of achievement of HbA1c goal less than 7.0. Diabetes Obes Metab. 2019;21:321\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"2830_CR31","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.diabet.2017.03.001","volume":"43","author":"Y Terauchi","year":"2017","unstructured":"Terauchi Y, Koyama M, Cheng X, et al. Glycaemic control and hypoglycaemia with insulin glargine 300 U\/mL compared with glargine 100 U\/mL in Japanese adults with type\u00a02 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension). Diabetes Metab. 2017;43:446\u201352.","journal-title":"Diabetes Metab"},{"key":"2830_CR32","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/dom.12618","volume":"18","author":"Y Terauchi","year":"2016","unstructured":"Terauchi Y, Koyama M, Cheng X, et al. New insulin glargine 300 U\/ml versus glargine 100 U\/ml in Japanese people with type\u00a02 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2). Diabetes Obes Metab. 2016;18:366\u201374.","journal-title":"Diabetes Obes Metab"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02830-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02830-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02830-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T17:12:36Z","timestamp":1714151556000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02830-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,21]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["2830"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02830-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2024,3,21]]},"assertion":[{"value":"2 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Won Kim and Dong Han Kim are employees of Sanofi Korea. Eun-Gyoung Hong, Kyung-Wan Min, Jung Soo Lim, Kyu-Jeung Ahn, Chul Woo Ahn, Hye\u00a0Soon Kim, Hyun Jin Kim, and Hak Chul Jang declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines and was approved by the institutional review board at each of the 27 study sites (see Supplementary Materials Table\u00a0), starting from first approval at Kyung Hee University Hospital at Gangdong Institutional Review Board (Approval code KHNMC 2016-05-005, Approval date 2016\u201305-20). All participants provided written, informed consent prior to enrollment and for anonymized patient information to be published in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}